Trevena (NASDAQ:TRVN – Get Free Report) and Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.
Institutional & Insider Ownership
13.6% of Trevena shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings for Trevena and Decoy Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trevena | 0 | 0 | 0 | 0 | 0.00 |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Risk and Volatility
Trevena has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Decoy Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Valuation and Earnings
This table compares Trevena and Decoy Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trevena | $443,000.00 | 0.02 | -$40.29 million | ($47.04) | 0.00 |
| Decoy Therapeutics | N/A | N/A | -$12.52 million | ($106.90) | -0.06 |
Decoy Therapeutics has lower revenue, but higher earnings than Trevena. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Trevena and Decoy Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trevena | N/A | N/A | -119.55% |
| Decoy Therapeutics | N/A | -395.42% | -193.30% |
Summary
Trevena beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.
About Trevena
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
